The use of mometasone and levocetirizine, desloratadine in the treatment of allergic diseases Case report
Article Sidebar
Published:
Nov 30, 2021
Keywords:
allergic rhinitis, glucocorticosteroids, second-generation antihistamines
Main Article Content
Abstract
The therapy of allergic diseases plays a critical role in the good control of the disease. The main group of drugs used in allergic rhinitis are intranasal glucocorticosteroids including mometasone, which effectively inhibits the inflammatory process, reduces swelling and irritation. On the other hand, second-generation antihistamines including levocetirizine and desloratadine are among the most popular and the most studied drugs used in allergic diseases. What they all have in common is their high safety profile, which makes these groups of drugs not only reliable but also effective.
Downloads
Download data is not yet available.
Article Details
How to Cite
Samoliński , B., Wojas , O., & Krzych-Fałta , E. (2021). The use of mometasone and levocetirizine, desloratadine in the treatment of allergic diseases. Alergoprofil, 17(4), 31-37. https://doi.org/10.24292/01.AP.174301121
Issue
Section
THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Samoliński B, Raciborski F, Lipiec A et al. Epidemiologia Chorób Alergicznych w Polsce (ECAP). Alergol Pol. 2014; 1(1): 10-8.
2. Raciborski F, Kłak A, Czarnecka-Operacz M et al. Epidemiology of urticaria in Poland – nationally representative survey results. Postepy Dermatol Alergol. 2018; 35(1): 67-73. http://doi.org/10.5114/ada.2018.73165.
3. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010; 126: 466-76.
4. Samoliński B, Arcimowicz M (ed). Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergol Pol – Polish J Alergol. 2013; S1: 1-167.
5. Raciborski F, Bousquet J, Namysłowski A et al. Correction to: Dissociating polysensitization and multimorbidity in children and adults from a Polish general population cohort. Clin Transl Allergy. 2019; 9: 23. http://doi.org/10.1186/s13601-019-0263-x.
6. Akkas H, Aydin E, Türkoglu Babakurban S et al. Effect of mometasone fu roate nasal spray on the DNA of nasal mucosal cells. Turk J Med Sci. 2018; 48(2): 339-45.
7. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
8. Ciprandi G, Varricchio A. The relevance of the Mometasone furoate nasal spray in clinical practice. J Biol Regul Homeost Agents. 2018; 32(4): 1051-4.
9. Eztom (mometazon [furoinian mometazonu]) – aerozol do nosa, zawiesina. (access: 15.10.2021).
10. Hitaxa. (access: 15.10.2021).
11. Contrahist. (access: 15.10.2021).
12. Sadowska-Woda I, Bieszczad-Bedrejczuk E. Spektrum działania farmakologicznego desloratadyny. Alerg Astma Immunol. 2010; 15(4): 189-96.
13. http://ec.europa.eu. Aneks i charakterystyka produktu leczniczego Desloratadine ratiopharm 5 mg, tabletki powlekane.
14. Rygalski M, Zawisza E. Atrybuty nowoczesnego leku przeciwhistaminowe. Lek w Polsce. 2015; 25(3): 20-5.
15. Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr. 2006; 82(5 suppl): 173-80.
16. Passali D, Spinosi MC, Crisanti A et al. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016; 11: 18. http://doi.org/10.1186/s40248-016-0054-3.
17. Kim DH, Kim BY, Shin JH et al. Intranasal azelastine and mometasone exhibit a synergistic effect an a murine model of allergic rhinitis. Am J Otolaryngol. 2017; 38(2): 198-203.
18. Staevska M, Popov TA, Kralimarkova T et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticarial. J. Allergy Clin Immunol. 2010; 125(3): 676-82.
19. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012; 4: 326-31.
20. Horak F, Stubner UP, Zieglmayer R et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis. Allergy. 2000; 279, abstract.
21. Marciniak-Bocheńska M, Kupczyk M, Bogacka E et al. Wpływ desloratadyny w dawce 5 mg na dobę na częstość stosowania B2 agonistów oraz objawy nieżytu nosa i astmy oskrzelowej u pacjentów z sezonowym alergicznym nieżytem błony śluzowej jamy nosa. Pneumonol Alergol Pol. 2004; 72: 296-307.
22. Reinartz SM, Overbeek SE, Kleinjan A et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy. 2005; 60(10): 1301-7.
23. Narbutt J. Leki przeciwhistaminowe II generacji w praktyce codziennej. Pediatr Med Rodz. 2012; 8(4): 351-9.
24. Panek M, Pietras T, Kuna P. Leki antyhistaminowe – kiedy i jak stosować w chorobach alergicznych. Terapia. 2014; 3(1): 23-9.
25. Ciebiada M, Ciebiada-Górska M, Górski P. Desloratadyna w leczeniu całorocznego alergicznego nieżytu nosa – wieloośrodkowe badanie w Polsce. Alerg Astma Immunol. 2002; 8(2): 101-5.
26. Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: a systematic review and meta-analysis. Biomed Pharmacother. 2016; 83: 989-97.
27. Tatar EC, Surenoglu UA, Ozdek A et al. The effect of combined medical treatment on quality of life in persistent allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2013; 65(Suppl 2): 333-7.
28. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005; 5(13-14): 1800-8.
29. O`Donnel BF, Lawor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2): 197-201.
30. Contrahist. (access: 15.10.2021).
2. Raciborski F, Kłak A, Czarnecka-Operacz M et al. Epidemiology of urticaria in Poland – nationally representative survey results. Postepy Dermatol Alergol. 2018; 35(1): 67-73. http://doi.org/10.5114/ada.2018.73165.
3. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010; 126: 466-76.
4. Samoliński B, Arcimowicz M (ed). Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergol Pol – Polish J Alergol. 2013; S1: 1-167.
5. Raciborski F, Bousquet J, Namysłowski A et al. Correction to: Dissociating polysensitization and multimorbidity in children and adults from a Polish general population cohort. Clin Transl Allergy. 2019; 9: 23. http://doi.org/10.1186/s13601-019-0263-x.
6. Akkas H, Aydin E, Türkoglu Babakurban S et al. Effect of mometasone fu roate nasal spray on the DNA of nasal mucosal cells. Turk J Med Sci. 2018; 48(2): 339-45.
7. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
8. Ciprandi G, Varricchio A. The relevance of the Mometasone furoate nasal spray in clinical practice. J Biol Regul Homeost Agents. 2018; 32(4): 1051-4.
9. Eztom (mometazon [furoinian mometazonu]) – aerozol do nosa, zawiesina. (access: 15.10.2021).
10. Hitaxa. (access: 15.10.2021).
11. Contrahist. (access: 15.10.2021).
12. Sadowska-Woda I, Bieszczad-Bedrejczuk E. Spektrum działania farmakologicznego desloratadyny. Alerg Astma Immunol. 2010; 15(4): 189-96.
13. http://ec.europa.eu. Aneks i charakterystyka produktu leczniczego Desloratadine ratiopharm 5 mg, tabletki powlekane.
14. Rygalski M, Zawisza E. Atrybuty nowoczesnego leku przeciwhistaminowe. Lek w Polsce. 2015; 25(3): 20-5.
15. Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr. 2006; 82(5 suppl): 173-80.
16. Passali D, Spinosi MC, Crisanti A et al. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016; 11: 18. http://doi.org/10.1186/s40248-016-0054-3.
17. Kim DH, Kim BY, Shin JH et al. Intranasal azelastine and mometasone exhibit a synergistic effect an a murine model of allergic rhinitis. Am J Otolaryngol. 2017; 38(2): 198-203.
18. Staevska M, Popov TA, Kralimarkova T et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticarial. J. Allergy Clin Immunol. 2010; 125(3): 676-82.
19. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012; 4: 326-31.
20. Horak F, Stubner UP, Zieglmayer R et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis. Allergy. 2000; 279, abstract.
21. Marciniak-Bocheńska M, Kupczyk M, Bogacka E et al. Wpływ desloratadyny w dawce 5 mg na dobę na częstość stosowania B2 agonistów oraz objawy nieżytu nosa i astmy oskrzelowej u pacjentów z sezonowym alergicznym nieżytem błony śluzowej jamy nosa. Pneumonol Alergol Pol. 2004; 72: 296-307.
22. Reinartz SM, Overbeek SE, Kleinjan A et al. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy. 2005; 60(10): 1301-7.
23. Narbutt J. Leki przeciwhistaminowe II generacji w praktyce codziennej. Pediatr Med Rodz. 2012; 8(4): 351-9.
24. Panek M, Pietras T, Kuna P. Leki antyhistaminowe – kiedy i jak stosować w chorobach alergicznych. Terapia. 2014; 3(1): 23-9.
25. Ciebiada M, Ciebiada-Górska M, Górski P. Desloratadyna w leczeniu całorocznego alergicznego nieżytu nosa – wieloośrodkowe badanie w Polsce. Alerg Astma Immunol. 2002; 8(2): 101-5.
26. Wei C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: a systematic review and meta-analysis. Biomed Pharmacother. 2016; 83: 989-97.
27. Tatar EC, Surenoglu UA, Ozdek A et al. The effect of combined medical treatment on quality of life in persistent allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2013; 65(Suppl 2): 333-7.
28. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005; 5(13-14): 1800-8.
29. O`Donnel BF, Lawor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2): 197-201.
30. Contrahist. (access: 15.10.2021).